SCNI: Scinai Immunotherapeutics Growth-Adjusted Market Cap to Net Income

Brandmark of Scinai Immunotherapeutics (SCNI)

Scinai Immunotherapeutics develops unique nanoantibodies to combat inflammation, secured by patents. The business relies on its monopoly status and the GMP certification of its Jerusalem laboratories. The PEG ratio history illustrates the valuation dynamics, where the current status is 0.00. Leading immunologists drive the project's development, utilizing access to cutting-edge R&D funding for the therapy of autoimmune pathologies.

SCNI Scinai: Price/Earnings to Growth Ratio in the range 02/21/2024 - 11/16/2026

Metric breakdowns and analytics for Scinai (SCNI)

- share price and consensus valuation forecast:
General company analysis:SCNI - BiondVax Pharmaceuticals
Signature product of Scinai Immunotherapeutics Ltd

The PEG ratio compares the current P/E multiple with earnings growth rates, determining whether the business expansion dynamics justify the market value of the shares. By analyzing this indicator of balance between valuation and growth, an investor can assess the potential of Scinai Immunotherapeutics (SCNI) through the lens of nano-antibody commercialization and success in clinical trials for psoriasis therapy.

Competitors of Scinai Immunotherapeutics

ARGX (Argenx) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (biontech.de)|Growth-Adjusted Market Cap to Net Income Abivax S.A. (ABVX)|ADMA - Price/Earnings to Growth Ratio|Protagonist Therapeutics, Inc. (PTGX) - Price/Earnings to Growth Multiple|Immunovant Therapeutics (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals|Price/Earnings to Growth Multiple GRFS|PEG Multiple adaptivebiotech.com|Price/Earnings to Growth Ratio Celldex (CLDX)|Aurinia Pharmaceuticals Inc. - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (biocryst.com)|Vera Therapeutics, Inc. (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Therapeutics, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tourmaline Corp (TRML)|PGEN (precigen.com) - PEG Multiple|PEG Multiple Pharming Corp|Price/Earnings to Growth Multiple NKTR (Nektar)|UPB (Upstream Bio Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Zenas Bio ZBIO|IMNM: Growth-Adjusted P/E Ratio|GOSS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income KalVista Pharmaceuticals KALV|Septerna (SEPN) - Price/Earnings to Growth Ratio|pieris.com - Growth-Adjusted Payback Ratio|SVRA (Savara Inc) - PEG Multiple|RIGL: Growth-Adjusted Payback Ratio|PEG Multiple ANAB|ATXS (Astria Pharma) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio enGene Holdings Inc. ENGN|PEG Multiple RAPT Therapeutics Inc. RAPT|Aerovate Therapeutics - PEG Multiple|Price to Earnings Adjusted for Growth Rate Aclaris Therapeutics Inc.|Kyverna (KYTX) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Tiziana Life Sciences (TLSA)|Price/Earnings to Growth Ratio Cabaletta Bio Inc.|Ventyx Biosciences (VTYX) - Growth-Adjusted Market Cap to Net Income|PEG Multiple THTX|PEG Multiple Avalo Therapeutics Inc. (AVTX)|PEG Multiple ELDN (eledon.com)|AGEN - Price/Earnings to Growth Multiple|CLYM: Price/Earnings to Growth Multiple|ZURA (Zura Bio Limited) - Growth-Adjusted P/E Ratio|ATYR: PEG Multiple|Adagene (ADAG) - PEG Multiple|IMA (ikenaoncology.com) - PEG Multiple|shattucklabs.com (STTK) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Equillium Inc (EQ)|Connect Pharma - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Immunic, Inc. IMUX|ATRA - Price/Earnings to Growth Multiple|IFRX - Price/Earnings to Growth Ratio|XFOR: Price/Earnings to Growth Ratio|ACET: PEG Multiple|Celularity Corp (CELU) - PEG Multiple|Price/Earnings to Growth Ratio INmune Bio|Barinthus Biotherapeutics plc (BRNS) - Growth-Adjusted Market Cap to Net Income|PEG Multiple KZR|SABS: Market Cap to Earnings and Growth Ratio|PEG Multiple AKTX (Akari Therapeutics, Plc)|ENLV (Enlivex Therapeutics, Ltd.) - Market Cap to Earnings and Growth Ratio|QTTB: Price/Earnings to Growth Multiple|GOVX - PEG Multiple|Edesa Biotech Corp (EDSA) - Price/Earnings to Growth Ratio|IBIO - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio carismatx.com|XTLB: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Bolt Biotherapeutics Inc. (BOLT)|HCWB (HCW Biologics) - Growth-Adjusted Payback Ratio|Aptevo Therapeutics - Price/Earnings to Growth Multiple|PEG Multiple AIM ImmunoTech Inc. AIM|Aditxt Inc. - PEG Multiple|Growth-Adjusted Payback Ratio GRI (GRI Bio, Inc.)|XORTX Therapeutics Inc (XRTX) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple ReShape Lifesciences|Price/Earnings to Growth Multiple REVB|Indaptus Corp (INDP) - Growth-Adjusted Market Cap to Net Income|PEG Multiple CALI|Price/Earnings to Growth Multiple Affimed N.V. AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics ITOS|Ocean Biomedical (OCEA) - Price/Earnings to Growth Ratio|tcbiopharm.com (TCBP) - PEG Multiple|THRD (Third Harmonic Bio Inc.) - PEG Multiple